Investment Counsel Company of Nevada’s Gilead Sciences GILD Stock Holding History

Investment Counsel Company of Nevada’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.82K	Buy	+54	New	+$7.12K	0.01%	105

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Investment Counsel Company of Nevada's GILD Position: Q2 2026 in Review

Investment Counsel Company of Nevada opened a new position in Gilead Sciences (GILD) in Q2 2026: 54 shares worth $6.82K. The stake represents 0.01% of the portfolio and ranks #105 among its holdings.

1,755 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Investment Counsel Company of Nevada held 54 shares of Gilead Sciences worth $6.82K as of Q2 2026.
Gilead Sciences was a new Investment Counsel Company of Nevada position in Q2 2026.
Gilead Sciences made up 0.01% of Investment Counsel Company of Nevada's portfolio in Q2 2026, its #105 holding.
1,755 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Investment Counsel Company of Nevada's 13F filing for Q2 2026, filed 10 Aug 2026.